- Home
- PFO vs HLVX Comparison
PFO vs HLVX Comparison
Compare PFO & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- HLVX
- Stock Information
- Founded
- PFO 1991
- HLVX 2020
- Country
- PFO United States
- HLVX United States
- Employees
- PFO N/A
- HLVX N/A
- Industry
- PFO Finance Companies
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- PFO Finance
- HLVX Health Care
- Exchange
- PFO Nasdaq
- HLVX Nasdaq
- Market Cap
- PFO 121.4M
- HLVX 104.3M
- IPO Year
- PFO N/A
- HLVX 2022
- Fundamental
- Price
- PFO $9.27
- HLVX $2.06
- Analyst Decision
- PFO
- HLVX Hold
- Analyst Count
- PFO 0
- HLVX 1
- Target Price
- PFO N/A
- HLVX $2.00
- AVG Volume (30 Days)
- PFO 31.8K
- HLVX 981.8K
- Earning Date
- PFO 01-01-0001
- HLVX 08-06-2025
- Dividend Yield
- PFO 6.51%
- HLVX N/A
- EPS Growth
- PFO N/A
- HLVX N/A
- EPS
- PFO N/A
- HLVX N/A
- Revenue
- PFO N/A
- HLVX N/A
- Revenue This Year
- PFO N/A
- HLVX N/A
- Revenue Next Year
- PFO N/A
- HLVX N/A
- P/E Ratio
- PFO N/A
- HLVX N/A
- Revenue Growth
- PFO N/A
- HLVX N/A
- 52 Week Low
- PFO $6.90
- HLVX $1.34
- 52 Week High
- PFO $8.51
- HLVX $2.17
- Technical
- Relative Strength Index (RSI)
- PFO 51.40
- HLVX 48.76
- Support Level
- PFO $9.20
- HLVX $2.05
- Resistance Level
- PFO $9.31
- HLVX $2.10
- Average True Range (ATR)
- PFO 0.06
- HLVX 0.02
- MACD
- PFO -0.01
- HLVX -0.00
- Stochastic Oscillator
- PFO 44.44
- HLVX 27.27
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.